66 results match your criteria: "Center of Drug Evaluation and Research[Affiliation]"

Improvement of physicochemical properties of an antiepileptic drug by salt engineering.

AAPS PharmSciTech

September 2012

Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, White Oak, LS Building 64, Room 1070, 10903 New Hampshire Ave., Silver Spring, Maryland 20993-002, USA.

The focus of the present investigation was to evaluate the feasibility of using cyclamic salt of lamotrigine in order to improve its solubility and intrinsic dissolution rate (IDR). The salt was prepared by solution crystallization method and characterized chemically by fourier transform infrared spectroscopy (FTIR), proton ((1)H) and carbon ((13)C) nuclear magnetic resonance (liquid and solid, NMR) spectroscopy, physically by powder X-ray diffraction (PXRD), thermally by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA), physicochemically for solubility, IDR, solution and solid-state stability, and polymorphism by solution recrystallization and slurry conversion studies. The FTIR, NMR, PXRD, DSC, and TGA spectra and thermograms indicated the salt formation.

View Article and Find Full Text PDF

Tannate complexes of antihistaminic drug: sustained release and taste masking approaches.

Int J Pharm

January 2012

Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-002, USA.

The aim of this investigation was to evaluate the complexation potential of brompheniramine maleate (BPM) and tannic acid (TA) for sustained release and taste masking effects. The complexes (1:1-1:7 TA to BPM ratio) were prepared by the solvent evaporation method using methanol, phosphate buffer pH 6.8 or 0.

View Article and Find Full Text PDF

Physico-mechanical and stability evaluation of carbamazepine cocrystal with nicotinamide.

AAPS PharmSciTech

June 2011

Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993-002, USA.

The focus of this investigation was to prepare the cocrystal of carbamazepine (CBZ) using nicotinamide as a coformer and to compare its preformulation properties and stability profile with CBZ. The cocrystal was prepared by solution cooling crystallization, solvent evaporation, and melting and cryomilling methods. They were characterized for solubility, intrinsic dissolution rate, chemical identification by Fourier transform infrared spectroscopy, crystallinity by differential scanning calorimetry, powder X-ray diffraction, and morphology by scanning electron microscopy.

View Article and Find Full Text PDF

Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials.

Contemp Clin Trials

July 2011

Division of Biometric I, Office of Biostatistics, Office of Translational Sciences, Center of Drug Evaluation and Research (CDER), Food and Drug Administration, Silver Spring, MD 20993-0002,USA.

Dealing with high placebo response remains a big challenge to conventional clinical trials for psychiatric disorders. A widely-used design strategy is to implement a placebo lead-in phase prior to randomization. The sequentially parallel design (SPD) proposed by Fava et al.

View Article and Find Full Text PDF

Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin.

Pharm Dev Technol

October 2012

Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993-002, USA.

The aim of present research was to investigate the physicochemical, mechanical properties, and stability characteristics of cocrystal of carbamazepine (CBZ) using saccharin (SAC) as a coformer. The cocrystals were prepared by solubility method and characterized by pH-solubility profile, intrinsic dissolution by static disk method, and surface morphology by scanning electron microscopy (SEM), crystallinity by differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD), and mechanical properties by Heckel analysis. Stability of the cocrystals were assessed by storing them at 60 (°)C for two weeks, 25 (°)C/60%RH, 40 (°)C/75%RH and 40 (°)C/94%RH for one month and compared with the stability of CBZ.

View Article and Find Full Text PDF

To increase our understanding of important subject characteristics and design variables affecting the performance of oral moxifloxacin in thorough QT studies, population pharmacokinetic and concentration-QTc models were developed by pooling data from 20 studies. A 1-compartment model with first-order elimination described the pharmacokinetics. Absorption delay was modeled using 8 transit compartments.

View Article and Find Full Text PDF

The focus of present investigation was to assess the utility of non-destructive techniques in the evaluation of risperidone solid dispersions (SD) with methyl-β-cyclodextrin (MBCD) and subsequent incorporation of the SD into orally disintegrating tablets (ODT) for a faster release of risperidone. The SD was prepared by a solvent evaporation method and evaluated by scanning electron microscopy (SEM), Fourier transform infrared (FTIR), near infrared spectroscopy (NIR), NIR-chemical imaging (NIR-CI), powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC). DSC and XRD analysis indicated that crystallinity of SD has reduced significantly.

View Article and Find Full Text PDF

Non-destructive methods of characterization of risperidone solid lipid nanoparticles.

Eur J Pharm Biopharm

September 2010

Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-002, USA.

The objective of this investigation is to evaluate compositional variations and their interaction of the solid lipid nanoparticle (SLN) formulation of risperidone using response surface methodology of design of experiment (DOE) and subsequently, characterize the SLN by non-destructive methods of analysis. Box-Behnken DOE was constructed using drug (X(1)), lipid (X(2)) and surfactant (X(3)) level as independent factors. Compritol 888 ATO and sodium lauryl sulphate were used as lipid and surfactant, respectively.

View Article and Find Full Text PDF

Online monitoring of PLGA microparticles formation using Lasentec focused beam reflectance (FBRM) and particle video microscope (PVM).

AAPS J

September 2010

Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, White Oak, LS Building 64, Room 1070, 10903 New Hampshire Ave, Silver Spring, Maryland 20993-002, USA.

Knowledge of the effects of different product and process variability on microparticle characterization is essential for the successful development, optimization, and scale-up of an encapsulation process. In the current research, the qualitative application of the Lasentec focused beam reflectance (FBRM) system for online monitoring of microparticle size distribution was demonstrated. lasentec particle vision and measurement (PVM) images were also employed to follow up the steps of microparticle formation and ripening.

View Article and Find Full Text PDF

Formulation and evaluation of a protein-loaded solid dispersions by non-destructive methods.

AAPS J

June 2010

Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

The purpose of this investigation was to develop solid dispersion (SD) formulation of cyclosporine (CyA) using polyethylene glycol (PEG-6000) to enhance its dissolution rate followed by nondestructive method for the prediction of both drug and carrier. SD formulations were prepared by varying the ratio of CyA and PEG-6000 by solvent evaporation technique and characterized by dissolution, scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), powder X-ray diffraction (PXRD), near infrared (NIR) and near infrared chemical imaging (NIR-CI). Dissolution data revealed enhanced dissolution of CyA when compared with pure CyA.

View Article and Find Full Text PDF

Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design.

Int J Pharm

April 2010

Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-002, USA.

The aim of this investigation was to screen and understand the product variability due to important factors affecting the characteristics CyA-PLGA nanoparticles prepared by O/W emulsification-solvent evaporation method. Independent variables studied were cyclosporine A (CyA) (X(1)), PLGA (X(2)), and emulsifier concentration namely SLS (X(3)), stirring rate (X(4)), type of organic solvent employed (chloroform or dichloromethane, X(5)) and organic to aqueous phase ratio (X(6)). The nanoparticles properties considered were encapsulation efficiency (Y(1)), mean particle size (Y(2)), zeta potential (Y(3)), burst effect (Y(4)) and dissolution efficiency (Y(5)).

View Article and Find Full Text PDF

Spectral and spatial characterization of protein loaded PLGA nanoparticles.

J Pharm Sci

March 2010

Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

The objective of this study was to evaluate near infrared (NIR) spectroscopy and imaging as approaches to assess drug contents in poly(dl-lactide-co-glycolide) (PLGA) based nanoparticles of a model protein, cyclosporine A (CyA). A 6-factors 12-runs designed set of experiments with Plackett-Burman (PB) screening was applied in order to examine the effects of drug loading (X(1)), polymer loading (X(2)), emulsifier concentration (X(3)), stirring rate (X(4)), type of organic solvent (X(5)), and ratio of organic to aqueous phases' volumes (X(6)), on drug entrapment efficiency (EFF). After omitting the factors with nonsignificant influences on EFF, a reduced mathematical relationship, EFF = 48.

View Article and Find Full Text PDF

Melanomagenesis: overcoming the barrier of melanocyte senescence.

Cell Cycle

July 2008

Division of Monoclonal Antibody, Center of Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA.

Although melanoma ultimately progresses to a highly aggressive and metastatic disease that is typically resistant to currently available therapy, it often begins as a benign nevus consisting of a clonal population of hyperplastic melanocytes that cannot progress because they are locked in a state of cellular senescence. Once senescence is overcome, the nevus can exhibit dysplastic features and readily progress to more lethal stages. Recent advances have convincingly demonstrated that senescence represents a true barrier to the progression of many types of cancer, including melanoma.

View Article and Find Full Text PDF

Taurine chloramine, an oxidant derived from neutrophils, induces apoptosis in human B lymphoma cells through mitochondrial damage.

J Biol Chem

June 2005

Laboratory of Biochemistry, Division of Therapeutic Proteins, Center of Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.

Taurine chloramine (TN-Cl) is one of the most abundant compounds generated by activated neutrophils. In contrast to HOCl, which causes necrosis, TN-Cl is a potent inducer of apoptosis in tumor cells. Here we show that the apoptosis induced by TN-Cl in human B lymphoma cells is dependent upon oxidant-mediated mitochondrial damage, a decrease in mitochondrial membrane potential, and caspase-9 activation.

View Article and Find Full Text PDF

Group sequential design and analysis of clinical equivalence assessment for generic nonsystematic drug products.

J Biopharm Stat

May 2004

Office of Biostatistics/Office of Pharmacoepidemiology and Statistical Sciences, Center of Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20857, USA.

Clinical trials with therapeutical endpoints are designed with three arms to demonstrate both the efficacy and the equivalence of the test generic treatment and the reference treatment. A generic drug product is determined to be equivalent to the reference drug product if the ratio or difference between the mean responses is bounded within the pre-specified equivalence limits. Often the trials are oversized for the placebo arm.

View Article and Find Full Text PDF

Silver products for medical indications: risk-benefit assessment.

J Toxicol Clin Toxicol

July 1996

Center of Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, USA.

Background: Legitimate medicinal use of silver-containing products has dramatically diminished over the last several decades. Recently, however, some manufacturers have begun to enthusiastically promote oral colloidal silver proteins as mineral supplements and for prevention and treatment of many diseases. Indiscriminate use of silver products can lead to toxicity such as argyria.

View Article and Find Full Text PDF